Skip to content

LeMaitre Vascular LMAT Payments to Acquire Short-Term Investments

Payments to Acquire Short-Term Investments at other companies

Vericel logo
VericelVCEL

Other financials

Income statement

See full
Revenue$66.6M+11.2%
Gross profit$48.4M+16.8%
Operating income$17.8M+40.8%
Net income$15.7M+42.4%
EPS (diluted)$0.68+41.7%

Balance sheet

See full
Cash & equivalents$26.9M+6.0%
Total debt$20.9M+20.6%
Total equity$406.6M+17.0%
Total assets$629.5M+13.2%

Cash flow

See full
Operating cash flow$15.1M+67.0%
CapEx$2.8M+101%
Free cash flow$12.3M+60.8%

Valuation

See full
Market cap$2.11B+31.4%

Profitability

See full
Gross margin72.4%+3.6pp
Operating margin28.5%+5.1pp
Net margin24.3%+4.4pp
FCF margin30.9%+12.7pp

Returns & leverage

See full
Return on equity16.5%+2.8pp
Debt / equity0.1×0.0×
Current ratio14.3×-2.2×

Where this comes from

Reported directly by LeMaitre Vascular in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: LeMaitre Vascular’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LeMaitre Vascular's payments to acquire short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LeMaitre Vascular's payments to acquire short-term investments?
LeMaitre Vascular (LMAT) reported payments to acquire short-term investments of $150.87M in Q1 2026.
How has LeMaitre Vascular's payments to acquire short-term investments changed year-over-year?
LeMaitre Vascular's payments to acquire short-term investments increased by 5114.9% year-over-year, from $2.89M to $150.87M.
What is the long-term trend for LeMaitre Vascular's payments to acquire short-term investments?
Over 3 years (2022 to 2025), LeMaitre Vascular's payments to acquire short-term investments has grown at a 331.2% compound annual growth rate (CAGR), from $8M to $641.33M.